<DOC>
	<DOCNO>NCT00891592</DOCNO>
	<brief_summary>This protocol enroll subject advance hematologic malignancy suitable related unrelated donor undergo Stem Cell Transplant . In study , subject undergo Stem Cell Transplant use Cord Blood . Part cord blood use Stem Cell Transplant part cord blood send laboratory order grow T cell ( cord blood ) increase activity cord blood T cell . The purpose part study see safe give study subject activate T cell make small portion donor UCB unit immediately UCB transplant . Activated T cell use safely stem cell transplantation study past , never study UCB transplantation .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplant Hematological Malignancies</brief_title>
	<detailed_description>The main study intervention include CD3/CD28 ex vivo costimulated T cell derive thawed umbilical cord blood unit , co-infused follow myeloablative condition regimen . Activated T cell T cell activate laboratory exposure 2 compound molecule call CD3 CD28 ; T cell expose compound time , become activated `` stimulate '' may effective fighting infection , cancer cell , promote recovery red cell , white cell , platelet transplantation . At Hospital University Pennsylvania , activate T cell prepare Clinical Cell Vaccine Production Facility , also know CVPF .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion Criteria . Relapsed persistent advance hematologic malignancy ; incurable standard chemotherapy eligible allogeneic HSCT , include : CHRONIC MYELOGENOUS LEUKEMIA ( CML ) . Subjects accelerate blast phase subject chronic phase inadequate response Imatinib intolerant Imatinib . ACUTE MYELOGENOUS LEUKEMIA ( AML ) . Subject high risk disease first complete remission ( CR ) . High risk disease include follow cytogenetic abnormality : monosomy 7 , deletion 5 , trisomy 8 , inversion 3 , ( 3 ; 3 ) , ( 6 ; 9 ) , ( 6 ; 11 ) . Subjects complex cytogenetic abnormality ( 3 chromosomal abnormality ) . ACUTE MYELOGENOUS LEUKEMIA ( AML ) . Subjects diagnosis AML receive chemotherapy , radiation therapy biopsy show myelodysplastic syndrome . ACUTE MYELOGENOUS LEUKEMIA ( AML ) . Subjects persistent AML 2 cycle standard induction chemotherapy . ACUTE MYELOGENOUS LEUKEMIA ( AML ) . Subjects first complete remission . MYELODYSPLASTIC SYNDROME ( MDS ) . Subjects intermediate high risk disease base upon International Prognostic Scoring System . ACUTE LYMPHOBLASTIC LEUKEMIA ( ALL ) . Subjects Philadelphia Chromosome ( ( 9 ; 22 ) cytogenetic abnormality ) molecular documentation BCRABL translocation . ACUTE LYMPHOBLASTIC LEUKEMIA ( ALL ) . Subjects primary refractory disease subject 1st complete remission . NHL HODKIN 'S DISEASE . Subjects relapse follow autologous Stem Cell Transplant . INDOLENT NHL . Subjects progressive disease follow &gt; 2 regimen . MULTIPLE MYELOMA . Subjects relapse follow follow autologous Stem Cell Transplant . Adults age 2150 . Expected survival 4 week . Subjects suitable related unrelated donor Stem Cell Transplant . Subject suitable Umbilical Cord Blood ( UCB ) unit available . Subject : Ejection fraction &gt; 45 % ; DLCO.45 % predict ; Creatinine &lt; 2 ; Total bilirubin &lt; 2X normal ; Transaminases &lt; 2X normal . Subject capable give informed consent . Subject pregnant lactating . Subject uncontrolled infection . Subject active untreated disease involve central nervous system . Subject active uncontrolled medical condition would preclude participation protocol .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>ALL</keyword>
	<keyword>NHL</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Hodgkin 's</keyword>
</DOC>